NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. Market Capitalization on January 14, 2025: USD 2.53 B

NewAmsterdam Pharma Company N.V. Market Capitalization is USD 2.53 B on January 14, 2025, a 79.34% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

NewAmsterdam Pharma Company N.V. 52-week high Market Capitalization is USD 2.85 B on December 17, 2024, which is 12.42% above the current Market Capitalization.
NewAmsterdam Pharma Company N.V. 52-week low Market Capitalization is USD 1.35 B on January 17, 2024, which is -46.90% below the current Market Capitalization.
NewAmsterdam Pharma Company N.V. average Market Capitalization for the last 52 weeks is USD 1.84 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years